-

11:35:00 PM

SYN Stock News

SYN - Theriva Biologics Inc

09/30/22 8:00 AM

AMEX : SYN

clinical triallow float

Synthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory Retinoblastoma

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat

RHEA-AI

neutral

09/27/22 8:00 AM

AMEX : SYN

clinical triallow float

Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company

RHEA-AI

neutral

09/05/22 8:00 AM

AMEX : SYN

clinical triallow float

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics

RHEA-AI

neutral

08/11/22 8:00 AM

AMEX : SYN

earningslow float

Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results

-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional $3 million in gross proceeds from convertible preferred financing extends funding for business operations into Q1 2024- -Conference call and

RHEA-AI

neutral

08/04/22 4:05 PM

AMEX : SYN

conferenceslow float

Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that Company’s management will participate in one-on-one investor

RHEA-AI

neutral

08/04/22 8:00 AM

AMEX : SYN

conferencesearningslow float

Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, August 11,

RHEA-AI

neutral

07/29/22 4:05 PM

AMEX : SYN

low float

Synthetic Biologics Announces $3 Million Private Placement of Convertible Preferred Stock

Synthetic Biologics, Inc.. (NYSE American: SYN) (“Synthetic Biologics” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the private placement of

RHEA-AI

neutral

07/15/22 8:00 AM

AMEX : SYN

low float

Synthetic Biologics Announces Reverse Stock Split

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstanding common stock,

RHEA-AI

neutral

05/16/22 8:00 AM

AMEX : SYN

earningslow float

Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results

-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and an upcoming oral presentation on VCN-11, a novel oncolytic adenovirus designed to evade neutralizing antibodies- -

RHEA-AI

neutral

05/10/22 8:00 AM

AMEX : SYN

clinical triallow float

Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of

RHEA-AI

neutral

SYN Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.syntheticbiologics.com
CeoSteven Shallcross
Security nameTheriva Biologics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees10
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address9605 Medical Center Dr Ste 270
StateMaryland
CityRockville
Zip20850-6382
CountryUS
Phone17343327800

About Theriva Biologics Inc

Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.